{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:42:11Z","timestamp":1787852531989,"version":"build-2784847793"},"reference-count":35,"publisher":"Frontiers Media SA","issue":"12","license":[{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,9,8]],"date-time":"2017-09-08T00:00:00Z","timestamp":1504828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1111\/tri.13022","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T08:32:40Z","timestamp":1502526760000},"page":"1275-1283","source":"Crossref","is-referenced-by-count":38,"title":["Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled<i>post hoc<\/i>analysis"],"prefix":"10.3389","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-2948","authenticated-orcid":false,"given":"Christophe M.","family":"Legendre","sequence":"first","affiliation":[{"name":"Adult Kidney Transplant Unit; Universit\u00e9 Paris Descartes and H\u00f4pital Necker; Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Campistol","sequence":"additional","affiliation":[{"name":"Renal Transplant Unit; Nephrology and Urology Department; Hospital Clinic; University of Barcelona; Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Feldkamp","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension; University Hospital Schleswig-Holstein; Christian Albrechts University Kiel; Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[{"name":"Unit of Nephrology; Division of Nephrology and Dialysis; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; Centro Anna Maria Astori; Azienda Ospedaliera Ospedale Papa Giovanni XXIII; Bergamo Italy"},{"name":"Department of Biomedical and Clinical Science; L. Sacco; University of Milan; Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Kincaid","sequence":"additional","affiliation":[{"name":"Global Medical Affairs; Alexion Pharmaceuticals, Inc.; New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Lommel\u00e9","sequence":"additional","affiliation":[{"name":"Medical & Scientific Communication; Alexion Pharma GmbH; Z\u00fcrich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Wang","sequence":"additional","affiliation":[{"name":"Biostatistics; Alexion Pharmaceuticals, Inc.; New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent E.","family":"Weekers","sequence":"additional","affiliation":[{"name":"Service of Nephrology, Dialysis and Transplantation; Centre Hospitalier Universitaire de Li\u00e8ge; Li\u00e8ge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Sheerin","sequence":"additional","affiliation":[{"name":"Institute of Cellular Medicine; Newcastle University; Newcastle upon Tyne UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"10.1111\/tri.13022-BIB0001|tri13022-cit-0001","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.13022-BIB0002|tri13022-cit-0002","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/tri.13022-BIB0003|tri13022-cit-0003","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/tri.13022-BIB0004|tri13022-cit-0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer","year":"2014","journal-title":"Front Pediatr"},{"key":"10.1111\/tri.13022-BIB0005|tri13022-cit-0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.13022-BIB0006|tri13022-cit-0006","volume-title":"Soliris (Eculizumab) [Prescribing Information]","author":"US Food and Drug Administration","year":"2017"},{"key":"10.1111\/tri.13022-BIB0007|tri13022-cit-0007","volume-title":"Soliris (Eculizumab) [Summary of Product Characteristics]","author":"European Medicines Agency","year":"2017"},{"key":"10.1111\/tri.13022-BIB0008|tri13022-cit-0008","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.13022-BIB0009|tri13022-cit-0009","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1111\/tri.13022-BIB0010|tri13022-cit-0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1111\/tri.13022-BIB0011|tri13022-cit-0011","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"Suppl. 3","key":"10.1111\/tri.13022-BIB0012|tri13022-cit-0012","doi-asserted-by":"crossref","first-page":"iii26","DOI":"10.1093\/ndt\/gfv146.05","article-title":"Normalisation of renal function following early initiation of eculizumab in patients with atypical haemolytic uraemic syndrome: pooled analysis of prospective clinical trials [abstract SaO008]","volume":"30","author":"Delmas","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.13022-BIB0013|tri13022-cit-0013","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.13022-BIB0014|tri13022-cit-0014","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1111\/tri.13022-BIB0015|tri13022-cit-0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/tri.13022-BIB0016|tri13022-cit-0016","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"10.1111\/tri.13022-BIB0017|tri13022-cit-0017","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.12864","article-title":"Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort","volume":"45","author":"Mallett","year":"2015","journal-title":"Intern Med J"},{"key":"10.1111\/tri.13022-BIB0018|tri13022-cit-0018","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.13022-BIB0019|tri13022-cit-0019","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s00467-011-1879-9","article-title":"Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome","volume":"26","author":"Weitz","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/tri.13022-BIB0020|tri13022-cit-0020","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2012.01497.x","article-title":"Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft","volume":"25","author":"Alachkar","year":"2012","journal-title":"Transpl Int"},{"key":"10.1111\/tri.13022-BIB0021|tri13022-cit-0021","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1111\/j.1600-6143.2012.04051.x","article-title":"Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH\/CFHR1 hybrid protein","volume":"12","author":"Krid","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.13022-BIB0022|tri13022-cit-0022","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1016\/j.transproceed.2012.07.141","article-title":"Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report","volume":"44","author":"Xie","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1111\/tri.13022-BIB0023|tri13022-cit-0023","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/ndt\/gft340","article-title":"Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions","volume":"28","author":"Bekassy","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.13022-BIB0024|tri13022-cit-0024","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/TP.0b013e31829d388d","article-title":"Anti-C5 as prophylactic therapy in atypical hemolytic uremic syndrome in living-related kidney transplantation","volume":"96","author":"Pelicano","year":"2013","journal-title":"Transplantation"},{"key":"10.1111\/tri.13022-BIB0025|tri13022-cit-0025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00467-013-2591-8","article-title":"Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH\/CFHR1 hybrid gene","volume":"29","author":"Roman-Ortiz","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/tri.13022-BIB0026|tri13022-cit-0026","first-page":"52","article-title":"Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature","volume":"1","author":"Alasfar","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"10.1111\/tri.13022-BIB0027|tri13022-cit-0027","doi-asserted-by":"crossref","first-page":"E185","DOI":"10.1111\/petr.12290","article-title":"Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation","volume":"18","author":"Ranch","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1111\/tri.13022-BIB0028|tri13022-cit-0028","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00467-013-2630-5","article-title":"Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation","volume":"29","author":"Tran","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/tri.13022-BIB0029|tri13022-cit-0029","doi-asserted-by":"crossref","first-page":"22","DOI":"10.23861\/EJBM201530635","article-title":"Preemptive use of eculizumab for living-donor kidney transplantation in a child with atypical hemolytic uremic syndrome","volume":"30","author":"Akchurin","year":"2015","journal-title":"Einstein J Biol Med"},{"key":"10.1111\/tri.13022-BIB0030|tri13022-cit-0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/tri.12440","article-title":"Living-donor kidney transplantation for atypical haemolytic uremic syndrome with pre-emptive eculizumab use","volume":"28","author":"Parikova","year":"2015","journal-title":"Transpl Int"},{"key":"10.1111\/tri.13022-BIB0031|tri13022-cit-0031","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00467-015-3278-0","article-title":"Liver transplantation for aHUS: still needed in the eculizumab era?","volume":"31","author":"Coppo","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1111\/tri.13022-BIB0032|tri13022-cit-0032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","article-title":"The global aHUS registry: methodology and initial patient characteristics","volume":"16","author":"Licht","year":"2015","journal-title":"BMC Nephrol"},{"key":"10.1111\/tri.13022-BIB0033|tri13022-cit-0033","first-page":"23A","article-title":"Timing of eculizumab treatment and the need for dialysis in patients with aHUS who receive a kidney transplant [abstract TH-OR095]","volume":"27","author":"Siedlecki","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/tri.13022-BIB0034|tri13022-cit-0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Vande Walle","year":"2017","journal-title":"J Nephrol"},{"key":"10.1111\/tri.13022-BIB0035|tri13022-cit-0035","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V120.21.3472.3472","article-title":"Eculizumab in paroxysmal nocturnal hemoglobinuria (PNH): a report of all 153 patients treated in the UK [abstract 3472]","volume":"120","author":"Hill","year":"2012","journal-title":"Blood"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.13022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.13022\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:40:17Z","timestamp":1641062417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.13022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.13022","archive":["Portico"],"relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,8]]}}}